Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc. (CYCC) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · CYCC · as of Jun 9, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
2
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Cyclacel Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
CYCC insider buying and selling by quarter
CYCC insider selling · CYCC insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · CYCC ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
CYCC executive sell shares · CYCC board member insider trading · CYCC insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Sep 5, 2025 | Kua Khai Loon 10 percent owner | Sale | 19,054 | $134K | Form 4 |
| Sep 4, 2025 | Yap Kim Choy 10 percent owner | Other | 186,465 | — | Form 4 |
| Sep 4, 2025 | Kua Khai Loon 10 percent owner | Other | 186,465 | — | Form 4 |
| Sep 4, 2025 | Ong Yee Lung 10 percent owner | Other | 186,465 | — | Form 4 |
| Jul 30, 2025 | Lazar David E. 10 percent owner | Sale | 6,750 | $83K | Form 4 |
| Feb 26, 2025 | Lazar David E. Interim CEO | Option | 191,978,820 | — | Form 4 |
| Feb 26, 2025 | Lazar David E. Interim CEO | Option | 2,650,000 | — | Form 4 |
| Feb 26, 2025 | Lazar David E. Interim CEO | Sale | 194,628,820 | $5.51M⚡ | Form 4 |
| Jan 2, 2025 | NATAN DAVID Director | Award | 100,000 | — | Form 4 |
| Jan 29, 2024 | SCHWARTZ BRIAN Interim Chief Medical Officer · Director | Award | 12,500 | — | Form 4 |
| Dec 21, 2023 | McBarron Paul See Remarks · Director | Purchase | 1,886 | $6K | Form 4 |
| Dec 21, 2023 | Rombotis Spiro George President and CEO · Director | Purchase | 6,070 | $20K | Form 4 |
| Jun 30, 2023 | BARKER SAM L Director | Award | 21,219 | — | Form 4 |
| Jun 30, 2023 | Spiegel Robert J. Director | Award | 21,219 | — | Form 4 |
| Jun 30, 2023 | Walker Karin L Director | Award | 21,219 | — | Form 4 |
| Jun 30, 2023 | Ferguson Kenneth M. Director | Award | 21,219 | — | Form 4 |
| Jun 30, 2023 | HENNEY CHRISTOPHER S Director | Award | 21,219 | — | Form 4 |
| Jun 30, 2023 | SCHWARTZ BRIAN Director | Award | 21,219 | — | Form 4 |
| Jan 31, 2023 | McBarron Paul See Remarks · Director | Award | 31,200 | — | Form 4 |
| Jan 31, 2023 | Rombotis Spiro George President and CEO · Director | Award | 57,600 | — | Form 4 |
| Jan 31, 2023 | Kirschbaum Mark Chief Medical Officer | Award | 31,200 | — | Form 4 |
| Jun 14, 2022 | Ferguson Kenneth M. Director | Award | 27,733 | — | Form 4 |
| Jun 14, 2022 | Sems Lloyd Director | Award | 15,822 | — | Form 4 |
| Jun 14, 2022 | SCHWARTZ BRIAN Director | Award | 15,822 | — | Form 4 |
| Jun 14, 2022 | HENNEY CHRISTOPHER S Director | Award | 15,822 | — | Form 4 |
Lazar David E.
Interim CEO
Date
Feb 26
Shares
194,628,820
Price
$0.03
Value
$5.51M ⚡
SCHWARTZ BRIAN
Interim Chief Medical Officer · Director
Date
Jan 29
Shares
12,500
Price
—
Value
—
McBarron Paul
See Remarks · Director
Date
Dec 21
Shares
1,886
Price
$3.31
Value
$6K
Rombotis Spiro George
President and CEO · Director
Date
Dec 21
Shares
6,070
Price
$3.31
Value
$20K
Rombotis Spiro George
President and CEO · Director
Date
Jan 31
Shares
57,600
Price
—
Value
—
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About CYCC insider trading
CYCC insider trades
Cyclacel Pharmaceuticals, Inc. (CYCC) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Kua Khai Loon (10 percent owner), Yap Kim Choy (10 percent owner), Ong Yee Lung (10 percent owner). Over the past 12 months, 4 insiders have filed transactions with the SEC. CYCC insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Cyclacel Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
CYCC insider trading · 5 questionsThe insiders of Cyclacel Pharmaceuticals, Inc. (CYCC) include executives and directors such as Kua Khai Loon (10 percent owner), Yap Kim Choy (10 percent owner), Ong Yee Lung (10 percent owner), among others. Over the past 12 months, 4 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026